Ultragenyx reported a record $214 million in total revenue for Q2 2026, driven by strong sales of Crysvita and Dojolvi. The company reaffirmed its 2026 revenue guidance of $730-$760 million and expects combined R&D and SG&A expenses to remain flat or slightly decrease compared to 2025. Key upcoming catalysts include FDA decisions on two gene therapies and pivotal Phase 3 data for GTX-102 in Angelman syndrome, positioning Ultragenyx for growth and profitability in 2027. Cash reserves stood at $436 million as of June 30, 2026, supporting ongoing operations and development programs.
American Eagle Outfitters reported strong Q2 results with earnings per share of $0.79, far exceeding the $0.22 estimate, and revenue of $1.38 billion, slightly above expectations. The growth was driven by a 25% revenue increase from its Aerie and OFF...
AeroVironment reported a strong quarterly earnings per share (EPS) of $0.59, well above analyst expectations of $0.22, showing solid profitability. However, its revenue of $329.06 million fell short of the estimated $451.95 million, reflecting mixed ...
Kuehn Law is investigating Picard Medical Inc. for possible breaches of fiduciary duty by its officers and directors. The lawsuit alleges that insiders engaged in a fraudulent stock promotion scheme using social media misinformation and fake financia...
Caleres reported a strong Q3 2026 earnings per share (EPS) of $0.47, surpassing analyst expectations by 27%, signaling improved profitability. However, its revenue of $695.45 million slightly missed estimates despite a 5.6% year-over-year increase, d...
Listen Labs, a startup using voice AI for customer interviews, walked away from a signed $125 million Series C funding round led by Menlo Ventures. The funding likely fell through due to ongoing acquisition talks with Salesforce, which is considering...
